Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates and …

We undertook this study to develop uniformly accepted criteria for the definition of organ
involvement and response for patients on treatment protocols for immunoglobulin light‐chain …

… A third boronate PI, CE P-18770, 16 was also in development, but data from clinical trials …
PN of any grade (38% vs 53%; P = .04), grade more than or equal to 2 (24% vs 41%; P = .01), …

Background Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation
antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with …

Purpose The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and
reliable tool is needed to stratify patients with MM. We combined the International Staging …

Background Daratumumab showed promising efficacy alone and with lenalidomide and
dexamethasone in a phase 1–2 study involving patients with relapsed or refractory multiple …

Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple
myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and …

Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and …

Background Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling
lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with …

Background Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed
CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory …